Autolus Limited

This early-stage study tests a new treatment called obe-cel for people with progressive multiple sclerosis (MS) that has not responded to other therapies. The main goal is to see if obe-cel is safe and what side effects it may cause. Eighteen adults will receive a single infusion…

This early-stage study tests a treatment called obecabtagene autoleucel (obe-cel) for people with severe lupus that hasn't responded to other therapies. Obe-cel uses a patient's own immune cells, modified to target and destroy faulty B cells that drive lupus. The main goals are t…

This study tests a new treatment called AUTO1 (Obe-cel) for children and teens with certain types of blood cancer that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attac…

This study tests a new treatment called obe-cel for people with severe lupus that has not responded to standard therapies and has caused active kidney inflammation (lupus nephritis). Obe-cel is designed to destroy harmful immune cells that drive the disease. The trial will enroll…

This program offers a special type of cell therapy called obe-cel to adults with a hard-to-treat blood cancer (ALL) who have run out of standard options. The treatment uses the patient's own immune cells, but the manufactured product didn't meet commercial standards. The goal is …